10.25.2021
Hebrew SeniorLife: “Social Determinants of Health Provide Better Understanding of Brain Vulnerability to Delirium: Hebrew SeniorLife Study Advances an Understanding of the Factors that Improve Health Outcomes in Older Adults”
10.07.2021
Hebrew SeniorLife: “Hebrew SeniorLife’s 8th Annual EngAGE Brings Entertainment with Mavis Staples and Mandy Patinkin: Raising Funds to Change the Way We Age for Future Generations”
09.14.2021
Seqens CDMO NA: “Seqens Appoints Bob Huang Managing Director of North American CDMO Operations:Sanofi Veteran to Expand Seqens’ Global Footprint, Build Upon Strong Local Presence”
09.10.2021
Regis College: “Regis College Offers Tuition Discounts to Hebrew SeniorLife Employees”
Hebrew SeniorLife: “Hebrew SeniorLife to Offer New Tuition Discount Benefit to All Employees; Agreements with Drexel, Quinnipiac, Regis, and Other Higher Ed Institutions Expand Learning Opportunities for Employees”
08.05.2021
Akston Biosciences: “Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine”
07.26.2021
Hebrew SeniorLife: “Hebrew SeniorLife Makes COVID-19 Vaccination a Condition of Employment: Effective October 1, 2021, Requirement Designed to Protect the Health and Safety of Patients, Residents, and Employees”
07.21.2021
Hebrew SeniorLife: “Hebrew SeniorLife Receives The John A. Hartford Foundation 2021 Business Innovation Award: n4a’s Aging and Disability Business Institute Recognized Hebrew SeniorLife for its Innovative Program that Integrates Health Care Services and Housing” (July 21, 2021)
Akston Bioscience: “Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale;New data shows protein-based AKS-452 vaccine is shelf-stable for six months at 25° C (77° F)”
07.08.2021
Akston Bioscience: “Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate”
03.23.2021
Lumen Technologies: “Lumen Technologies to host Analyst Day on Wednesday, April 7”
02.09.2021
Akston Biosciences: “Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats Follows earlier agreement between Akston and Dechra for AKS-321d, a once-a-week insulin therapy for dogs”
